海南省药品监督管理局关于2025年医疗器械质量抽查检验情况的通告 为加强医疗器械质量监管，保障公众用械安全，根据《医疗器械监督管理条例》等法规文件，海南省药品监督管理局按照《海南省2025年医疗器械抽检工作 实施方案》有关要求，组织对全省医疗器械生产、经营、使用环节进行医疗器械质量抽查检验，共抽检110批次，检验结果均符合规定。现将医疗器械抽查 检验情况予以通告（见附件）。 海南省药品监督管理局 2026年2月14日 海南省2025年医疗器械质量监督抽检情况统计表（共110批次） | 序 | 检验报告编号 医疗器械产品名称 | 规格/型号 | 批号/遍号 | 生产企业名称 | 抽样单位 | 检验 | | --- | --- | --- | --- | --- | --- | --- | | 号 | | | | | | 结果 | | 1 | HL2025QH0498 医用电子体温计 | DT007 | 221200608 | 广州市倍尔康医疗器械 | 海口市市场监督管 | 合格 | | | | | | 有限公司 | 理局 | | | 2 | HL2025QH0368 医用退热贴 | 120mm×50mm/普通型 ...

Group 1 - The FDA issued an early warning regarding a security vulnerability in the TRUE METRIX blood glucose meters from Trividia Health, a subsidiary of Sanofi, indicating 114 cases of serious injuries and 1 death reported [1] - The company has initiated corrective actions for product labeling and usage instructions, outlining a risk response plan [1] - This incident may have a short-term negative impact on the brand reputation and overseas business [1] Group 2 - As of February 24, 2026, Sanofi's stock price closed at 18.01 yuan, with a daily increase of 0.45% and a trading volume of 55.67 million yuan [2] - Over the past 5 days, the stock price has decreased by 1.10%, underperforming the market, with a net outflow of 6.05 million yuan in major funds, reflecting cautious market sentiment [2] - The company's share repurchase plan has been completed, with a total of 15.76 million shares repurchased, accounting for 2.81% of the total share capital, with a transaction amount of approximately 300 million yuan [2] Group 3 - Institutions maintain a neutral outlook on Sanofi, with a target price of 24.00 yuan, indicating a potential upside of 33.85% from the current stock price [3] - According to forecasts from 30 institutions, the net profit attributable to the parent company is expected to decline by 12.15% year-on-year in 2025, primarily due to patent and settlement costs [3] - A significant rebound is anticipated in 2026, with an expected year-on-year growth of 65.11%, driven by the expansion of CGM business and improvements in overseas operations [3]

Group 1: Key Highlights - Zhangyue Technology (掌阅科技) expects AI short drama business revenue to not exceed 1% of its main business revenue in 2025 [1][2] - Actual controller of Jialinjie (嘉麟杰), Li Zhaoting, has been subjected to compulsory measures [1][2] - Jindan Technology (金丹科技) increases investment in a project for an annual production of 75,000 tons of polylactic acid biodegradable materials [1][2] Group 2: Contract Awards - Qinglong Pipe Industry (青龙管业) wins the bid for the first section of the heat supply pipeline project from Pengyang County Wangwa Power Plant to the county [1][2] - Gaode Infrared (高德红外) signs a contract for a complete equipment system [1][2] - ST Xintong (ST信通) signs a server procurement contract worth approximately 400 million yuan [1][2] Group 3: Financial Performance - Hanzhong Precision Machinery (汉钟精机) reports a net profit of 470 million yuan for 2025, a decrease of 45.54% year-on-year [1][2] - Fudan Microelectronics (复旦微电) anticipates a net profit of approximately 232 million yuan for 2025, down about 59.42% year-on-year [1][2] - Ruilian New Materials (瑞联新材) expects a net profit of 311 million yuan for 2025, an increase of 23.48% year-on-year [1][2] Group 4: Equity Transactions - Gongjin Co. (共进股份) plans to transfer 21.8340% equity of Chip Material Technology to Xinchang Technology [1][2] - Shengquan Group (圣泉集团) intends to acquire 13.50% equity of Shangbo Pharmaceutical for 4.29 million USD [1][2] - Changjiang Communication (长江通信) plans to exit 4.66% equity of Hangzhou Chenxiao through a targeted capital reduction [1][2] Group 5: Share Buybacks - Hualing Steel (华菱钢铁) has repurchased 0.8109% of its shares [1][2] - SanNuo Bio (三诺生物) has completed a share buyback plan, repurchasing 2.81% of its shares [1][2] Group 6: Shareholding Changes - Chunqiu Electronics (春秋电子) plans to reduce holdings by no more than 2% [1][2] - Guanghuan New Network (光环新网) intends to reduce holdings by no more than 3% [1][2] - ST Yigou (ST易购) plans to reduce holdings by no more than 2.5% [1][2] - Changjiang Communication (长江通信) plans to sell no more than 1 million shares of Changfei Optical Fiber [1][2] Group 7: Other News - Yingjixin (英集芯) is under investigation by the China Securities Regulatory Commission for suspected information disclosure violations [1][2] - Tianfeng Securities (天风证券) has received a notice of investigation from the China Securities Regulatory Commission [1][2] - Chuangshi Technology (创识科技) reports that its controlling shareholder has received a criminal judgment [1][2]

证券日报网讯2月13日，三诺生物（300298）发布公告称，截至2026年2月13日，公司通过集中竞价累计 回购15755261股，占总股本2.81%，成交总额299974592.28元，回购方案实施完毕，股份将用于员工持 股、股权激励或可转债转换。 ...

格隆汇2月13日丨三诺生物(300298.SZ)公布，公司实际回购时间区间为2025年4月7日至2026年2月12 日。截至本公告披露日，公司通过股份回购专用证券账户以集中竞价交易方式累计回购公司股份1575.5 万股，占公司总股本的比例为2.81%，本次回购股份的最高成交价为21.39元/股，最低成交价为17.27元/ 股，成交总金额为3亿元（不含交易费用）。公司本次回购股份资金总额已超过本次回购方案中回购股 份资金总额下限，且不超过回购股份资金总额上限，符合公司既定的回购方案及相关法律法规的要求。 本次回购股份方案已实施完毕。 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 三诺生物传感股份有限公司（以下简称"公司"）于 2025 年 2 月 20 日召开 第五届董事会第十六次会议和第五届监事会第十二次会议，审议并通过《关于回 购公司部分股份方案的议案》，同意公司使用自有资金及银行回购专项贷款以集 中竞价交易的方式回购公司部分社会公众股份，用于员工持股计划、股权激励或 者用于转换上市公司发行的可转换为股票的公司债券。回购资金总额不低于人民 币 15,000 万元且不超过人民币 30,000 万元（均含本数），回购价格不超过人民币 34.00 元/股（含），实施期限为自董事会审议通过本次回购部分股份方案之日起 12 个月内。具体内容详见公司分别于 2025 年 2 月 20 日、2025 年 2 月 24 日在巨 潮资讯网（www.cninfo.com.cn）上披露的《关于回购公司部分股份方案暨取得金 融机构股票回购专项贷款承诺函的公告》（公告编号：2025-007）、《回购股份报 告书》（公告编号：2025-011）。 2025 年 6 月 13 日，公司实施完成 2024 年年度权 ...

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2026-022 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 公司股票自2025年12月22日至2026年2月3日连续三十个交易日的收盘价格 低于当期"三诺转债"转股价格34.46元/股的70%，即24.12元/股，且"三诺转债" 处于最后两个计息年度内，根据《三诺生物传感股份有限公司创业板向不特定对 象发行可转换公司债券募集说明书》（以下简称"《募集说明书》"）的相关约 定，"三诺转债"的有条件回售条款生效。 根据《深圳证券交易所上市公司自律监管指引第15号——可转换公司债券》 的相关规定，发行可转债的上市公司可转债实施回售的，应当暂停可转债转股。 三诺生物传感股份有限公司 关于三诺转债恢复转股的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 经中国证券监督管理委员会《关于三诺生物股份有限公司公开发行可转换公 司债券的批复》（证监许可〔2020〕2951号）核准，三诺生物传感股份有限公司 （以下简称"公司"）于 ...

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2026-021 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 关于三诺转债回售的第八次提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 11、"三诺转债"持有人有权选择是否进行回售，本次回售不具有强制性。 12、风险提示：投资者选择回售等同于以 100.274 元/张（含息、税）卖出 持有的"三诺转债"。截至目前，"三诺转债"的收盘价格高于本次回售价格， 投资者选择回售可能会带来损失，敬请投资者注意风险。 三诺生物传感股份有限公司（以下简称"公司"）的股票自 2025 年 12 月 22 日至 2026 年 2 月 3 日连续三十个交易日的收盘价格低于当期"三诺转债"转 股价格 34.46 元/股的 70%，即 24.12 元/股，且"三诺转债"处于最后两个计息 年度内，根据《三诺生物传感股份有限公司创业板向不特定对象发行可转换公司 1、债券简称：三诺转债 2、债券代码：123090 3、 ...

Core Viewpoint - The report from Guosen Securities indicates that the medical services and consumer-related sectors have experienced long-term adjustments, resulting in valuations at historical lows. By 2026, improvements in supply structure, increased treatment volumes, and store optimization are expected to lead to a dual recovery in fundamentals and valuations, with AI empowerment providing new momentum for leading companies [1][2]. Group 1: Medical Services and Consumer Sectors - The medical services and consumer-related sectors are currently undervalued and poised for performance recovery, with a focus on specific sub-sectors [2]. - In medical services, improvements in supply structure and consumer environment are anticipated to gradually revive business, with stable customer spending and increased treatment volumes. Leading companies are expected to provide positive earnings guidance for 2026, indicating a potential dual recovery in fundamentals and valuations. AI-related business developments are also expected to drive new growth for leading medical service firms. Key companies to watch include Aier Eye Hospital (300015), Gushengtang, Tongce Medical (600763), and Haijia Medical [2]. - The pharmacy sector has shown significant marginal improvement in performance since Q3 2025, with leading companies improving same-store performance quarterly. Regulatory support from nine ministries emphasizes the long-term development direction of industry concentration and chain rate enhancement, with non-pharmaceutical adjustments and store structure optimization driving short-term performance improvements. Key companies include Yifeng Pharmacy (603939) and Dazhenglin (603233) [2]. Group 2: Home Medical Devices - The growth of home medical device companies is driven by increased product penetration and domestic production rates. Rapid growth is observed in products like Continuous Glucose Monitors (CGM) and sleep apnea machines, with leading domestic brands expanding internationally. Traditional categories like blood pressure monitors are increasingly focusing on the high-end market, with domestic brands steadily increasing market share. The combination of high domestic growth and new overseas markets is expected to contribute to sustained performance growth for home medical device companies. Key companies include Yuyue Medical (002223), Kefu Medical (301087), Sanofi Biological (300298), and Ruimaite (301367) [3]. Group 3: Innovative Drug Development - The collaboration for the international expansion of innovative drugs continues to deepen, with recent significant agreements between Shiyao Group and AstraZeneca, as well as Innovent Biologics and Eli Lilly. These collaborations highlight the growing recognition of China's innovative drug development capabilities by multinational pharmaceutical companies, showcasing the efficiency and cost advantages of Chinese innovative drugs [4]. Group 4: Investment Portfolio for 2026 - The investment portfolio for 2026 includes A-shares such as Mindray Medical (300760), United Imaging Healthcare, WuXi AppTec (603259), New Industry (300832), Meihua Medical (301363), Adebiotech (300685), Zhend Medical (603301), Yaokang Biological, Kingmed Diagnostics (603882), Aier Eye Hospital, Yuyue Medical, Yifeng Pharmacy, and Dazhenglin; H-shares include Kangfang Biologics, Kelun-Botai Biologics-B, Hutchison China MediTech, Kangnuo-B, Sanofi Biopharma, Gushengtang, and Aikang Medical [5].

Core Viewpoint - The AI medical sector experienced a decline of 0.66% on February 11, with QianYuan Pharmaceutical leading the drop. The Shanghai Composite Index rose by 0.09%, while the Shenzhen Component Index fell by 0.35% [1]. Group 1: Market Performance - The closing price of QianYuan Pharmaceutical was 11.44, down by 4.67%, with a trading volume of 209,800 shares and a transaction value of 243 million [2]. - The AI medical sector saw a net outflow of 1.345 billion from major funds, while retail investors contributed a net inflow of 1.14 billion [2][3]. Group 2: Individual Stock Performance - YoukeDe (688158) closed at 37.54, up by 5.12%, with a trading volume of 631,000 shares and a transaction value of 2.36 billion [1]. - AidiTe (301580) closed at 55.18, up by 4.63%, with a trading volume of 46,100 shares and a transaction value of 251 million [1]. - SanNuo Biology (300298) closed at 18.54, up by 2.71%, with a trading volume of 105,200 shares and a transaction value of 194 million [1]. - The top decliners included QianYuan Pharmaceutical (300254) and KaiPu Biology (300639), with declines of 4.67% and 4.23%, respectively [2].